HMZS Biopharmaceutical Blacklisted After Failing to Monitor Production Process
Policy / Regulatory

HMZS Biopharmaceutical Blacklisted After Failing to Monitor Production Process

IceCure Medical Secures Chinese Patent for Cryogenic System Connector
CompanyMedical Device

IceCure Medical Secures Chinese Patent for Cryogenic System Connector

FibroGen Reports Decline in Sales, Pushes Ahead with Roxadustat and New Drug Development
Company

FibroGen Reports Decline in Sales, Pushes Ahead with Roxadustat and New Drug Development

Taiho Pharmaceutical to Acquire Araris Biotech for USD 400 Million, Expanding ADC Portfolio
CompanyDeals

Taiho Pharmaceutical to Acquire Araris Biotech for USD 400 Million, Expanding ADC Portfolio

Livzon Pharmaceutical Receives Approval for Clinical Trials of Adjuvanted Influenza Vaccine LZSN2401
CompanyDrug

Livzon Pharmaceutical Receives Approval for Clinical Trials of Adjuvanted Influenza Vaccine LZSN2401

Lifetech Scientific's Aortic Stent System Approved by China's NMPA
CompanyMedical Device

Lifetech Scientific’s Aortic Stent System Approved by China’s NMPA

PomDoctor Files for Nasdaq IPO to Expand Chronic Disease Management Services
CompanyDeals

PomDoctor Files for Nasdaq IPO to Expand Chronic Disease Management Services

Rona Therapeutics Initiates Phase II Study for RN0361 in Severe Hypertriglyceridemia
CompanyDrug

Rona Therapeutics Initiates Phase II Study for RN0361 in Severe Hypertriglyceridemia

Hengrui Pharmaceuticals Receives NMPA Clearance for HRS-6213 in Solid Tumor Diagnosis
CompanyDrug

Hengrui Pharmaceuticals Receives NMPA Clearance for HRS-6213 in Solid Tumor Diagnosis

Alphamab Oncology's JSKN033 Receives Breakthrough Therapy Designation for Platinum Resistant Ovarian Cancer
CompanyDrug

Alphamab Oncology’s JSKN033 Receives Breakthrough Therapy Designation for Platinum Resistant Ovarian Cancer

AstraZeneca to Acquire EsoBiotec for Up to $1 Billion to Boost Cell Therapy Portfolio
CompanyDeals

AstraZeneca to Acquire EsoBiotec for Up to $1 Billion to Boost Cell Therapy Portfolio

AstraZeneca Licenses Alteogen's ALT-B4 for Subcutaneous Cancer Therapies
CompanyDeals

AstraZeneca Licenses Alteogen’s ALT-B4 for Subcutaneous Cancer Therapies